{"id":241059,"date":"2026-05-07T12:30:00","date_gmt":"2026-05-07T16:30:00","guid":{"rendered":"https:\/\/news-you-need.com\/index.php\/2026\/05\/07\/yale-led-technology-receives-first-ever-fda-approval-for-breast-cancer-treatment\/"},"modified":"2026-05-07T12:45:07","modified_gmt":"2026-05-07T16:45:07","slug":"yale-led-technology-receives-first-ever-fda-approval-for-breast-cancer-treatment","status":"publish","type":"post","link":"https:\/\/news-you-need.com\/index.php\/2026\/05\/07\/yale-led-technology-receives-first-ever-fda-approval-for-breast-cancer-treatment\/","title":{"rendered":"Yale-led technology receives first-ever FDA approval for breast cancer treatment"},"content":{"rendered":"

Yale-led technology receives first-ever FDA approval for breast cancer treatment<\/a><\/p>\n

https:\/\/news.yale.edu\/2026\/05\/07\/yale-led-technology-receives-first-ever-fda-approval-breast-cancer-treatment<\/a><\/p>\n

Publish Date: 2026-05-07 12:30:00<\/a><\/p>\n

Source Domain: news.yale.edu<\/a><\/p>\n

More than a decade ago, Yale chemist Craig Crews founded a biotechnology company in New Haven based on his pioneering research into PROTAC<\/span>s (or PRO<\/span>teolysis TA<\/span>rgeting Chimera), a technology that treats certain types of cancer and other diseases by degrading the proteins that cause\u00a0them.\u00a0<\/p>\n

That company, Arvinas, has since developed a PROTAC<\/span> therapy called vepdegestrant, which is now helping patients living with breast\u00a0cancer.\u00a0<\/p>\n

Last week, vepdegestrant, which is developed by Arvinas and Pfizer under the brand name Veppanu, became the first PROTAC<\/span> therapy to be approved by the U.S.<\/span> Food and Drug\u00a0Administration.\u00a0<\/p>\n

The once-daily oral therapy will be available as treatment for adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1<\/span>-mutated advanced or metastatic breast cancer. Breast cancer is the most common cancer among women worldwide, with many tumors driven by estrogen receptor\u00a0signaling.<\/p>\n

For Crews, the FDA<\/span> approval of vepdegestrant as a treatment for breast cancer now has additional personal\u00a0meaning.\u00a0<\/p>\n

\u201cI\u2019m thrilled that breast cancer patients will have an additional option for treatment,\u201d said Crews, who is the John C. Malone Professor of Molecular, Cellular, and Developmental Biology and professor of chemistry in Yale\u2019s Faculty of Arts and Sciences and professor of pharmacology at Yale School of Medicine. \u201cMy mother was diagnosed last year with breast cancer, and so I know the challenges that patients and their families face with thinking about therapeutic\u00a0options.\u201d\u00a0<\/p>\n

Largely pioneered at Yale, PROTAC<\/span>s have already inspired dozens of other companies that are developing degrader therapies across numerous cancer\u00a0types.<\/p>\n

The FDA<\/span> approval of vepdegestrant will reinforce that momentum, Crews\u00a0said.<\/p>\n

\u201cPROTAC<\/span>s are a new class of drugs, and this first approval will encourage drug developers to explore the use of PROTAC<\/span>s for other diseases such as neurodegeneration (dementia) and other challenging diseases,\u201d…<\/p>\n

Source<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Yale-led technology receives first-ever FDA approval for breast cancer treatment https:\/\/news.yale.edu\/2026\/05\/07\/yale-led-technology-receives-first-ever-fda-approval-breast-cancer-treatment Publish Date: 2026-05-07 12:30:00…<\/p>\n","protected":false},"author":1,"featured_media":241060,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"fifu_image_url":"https:\/\/news.yale.edu\/sites\/default\/files\/styles\/opengraph_image\/public\/2025-12\/Craig-Crews_AI-2247240307_Siduma_.jpg?h=f78a16fc&itok=It0kLHnm","fifu_image_alt":"","footnotes":""},"categories":[8],"tags":[],"class_list":["post-241059","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-technology"],"_links":{"self":[{"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/posts\/241059"}],"collection":[{"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/comments?post=241059"}],"version-history":[{"count":1,"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/posts\/241059\/revisions"}],"predecessor-version":[{"id":241063,"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/posts\/241059\/revisions\/241063"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/media\/241060"}],"wp:attachment":[{"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/media?parent=241059"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/categories?post=241059"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/tags?post=241059"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}